IMAGING NETWORK FOR BREAST CANCER MASS SCREENING

Information

  • Research Project
  • 7286032
  • ApplicationId
    7286032
  • Core Project Number
    R44CA091392
  • Full Project Number
    5R44CA091392-05
  • Serial Number
    91392
  • FOA Number
    PAR-03-125
  • Sub Project Id
  • Project Start Date
    8/1/2001 - 24 years ago
  • Project End Date
    8/31/2008 - 17 years ago
  • Program Officer Name
    NORDSTROM, ROBERT J.
  • Budget Start Date
    5/1/2007 - 18 years ago
  • Budget End Date
    8/31/2008 - 17 years ago
  • Fiscal Year
    2007
  • Support Year
    5
  • Suffix
  • Award Notice Date
    4/24/2007 - 18 years ago

IMAGING NETWORK FOR BREAST CANCER MASS SCREENING

DESCRIPTION (provided by applicant): Early detection of breast cancer remains one of the most significant challenges in health care. The tactile breast imager (TBI) is a promising solution that electronically captures the sense of touch to provide a quantitative, sensitive, and permanent record of palpatory breast examination. Its inherent low cost, ease of use, and promising test results to date, give it great potential as an effective mass pre-screening tool for breast cancer detection. In Phase I, we successfully developed and tested a prototype device that showed sensitivity well beyond the manual palpation limit in a variety of test conditions. The device was tested on physical tissue models and demonstrated to robustly detect nodules of various sizes and subcutaneous depths. Advanced data processing algorithms were developed providing vivid 3-D images of the underlying mechanical tissue structure. In Phase II we will perform an initial clinical study to acquire raw image data and correlated lesion mechanical property data for use in refining the image processing and feature identification capabilities. We will concurrently build an advanced TBI prototype with substantially improved sensor performance. Clinical studies will be performed involving concurrent mammography / TBI imaging with qualitative comparative analysis between the modalities. We will conduct clinical development studies and build physical breast models to improve the data collection and lesion discrimination performance. The TBI will then be tested in a blinded clinical study to obtain statistically relevant measures of lesion sensitivity, specificity, and mechanical image quality. Appropriate regulatory testing will be conducted in order to prepare necessary engineering documentation for a FDA application.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    206640
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:206640\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARTANN LABORATORIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    TRENTON
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    08618
  • Organization District
    UNITED STATES